Equities

Shield Therapeutics PLC

STX:LSE

Shield Therapeutics PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)1.55
  • Today's Change-0.10 / -6.06%
  • Shares traded8.52m
  • 1 Year change-78.32%
  • Beta1.4942
Data delayed at least 20 minutes, as of May 03 2024 17:07 BST.
More ▼

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year Shield Therapeutics PLC had net income fall 151.04% from a loss of 19.68m to a larger loss of 49.40m despite a 261.55% increase in revenues from 1.52m to 5.49m.
Gross margin44.76%
Net profit margin-650.12%
Operating margin-635.87%
Return on assets-109.95%
Return on equity-140.45%
Return on investment-129.39%
More ▼

Cash flow in GBPView more

In 2022, cash reserves at Shield Therapeutics PLC fell by 13.00m. Cash Flow from Financing totalled 9.37m or 170.59% of revenues. In addition the company used 21.49m for operations while cash used for investing totalled 2.25m.
Cash flow per share-0.094
Price/Cash flow per share--
Book value per share0.038
Tangible book value per share0.0166
More ▼

Balance sheet in GBPView more

Shield Therapeutics PLC has a Debt to Total Capital ratio of 17.56%.
Current ratio2.95
Quick ratio2.64
Total debt/total equity0.213
Total debt/total capital0.1756
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.